Liposomes in Pediatric AML Treatment: New Study Results and Insights

A recent study published in the Journal of Clinical Oncology has revealed crucial information about the use of liposomes in treating pediatric Acute Myeloid Leukemia (AML). The research, conducted by a team of investigators from the University Health Network in Toronto, Canada, aimed to evaluate the effectiveness of liposomal daunorubicin compared to mitoxantrone in induction therapy for pediatric AML. The study involved 194 patients who were randomly assigned to either mitoxantrone or experimental liposomal daunorubicin in induction 1, with a primary end point of measuring residual disease by flow cytometry.

Key Takeaways:

• The study found that mitoxantrone had a superior anti-leukemic effect compared to liposomal daunorubicin, with a significantly lower proportion of patients with measurable residual disease (MRD) 5 years after induction therapy (56.6% vs. 71.9%).
• Cumulative incidence of relapse (CIR) was also higher for liposomal daunorubicin compared to mitoxantrone (35.1% vs. 18.8%).
• Inferior outcomes for liposomal daunorubicin were observed in standard-risk patients, with event-free survival (EFS) 5 years after induction therapy being significantly lower (55.3% vs. 79.9%).
• As-treated analyses, including the observation cohort, supported the results, with 85% of high-risk patients receiving hematopoietic stem-cell transplant (hSCT).
• The intensification of induction therapy with risk stratification based on response to induction and hSCT for high-risk patients led to improved outcomes.

Statistics:

• 194 patients were randomly assigned to mitoxantrone or experimental liposomal daunorubicin in induction 1.
• The primary end point was MRD, with 56.6% of patients on liposomal daunorubicin and 71.9% of patients on mitoxantrone having MRD 5 years after induction therapy.
• CIR was higher for liposomal daunorubicin (35.1%) compared to mitoxantrone (18.8%).
• EFS 5 years after induction therapy was significantly lower for liposomal daunorubicin (55.3%) in standard-risk patients.
• OS 5 years after induction therapy was significantly lower for liposomal daunorubicin (76.2%) in standard-risk patients.

Sources:

• Mitoxantrone Versus Liposomal Daunorubicin in Induction of Pediatric AML With Risk Stratification Based on Flow Cytometry Measurement of Residual Disease. Journal of Clinical Oncology, 2024, 42(18).
• American Society of Clinical Oncology (ASCO).